Biogen Inc. (BIIB) stock
BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3057% above fair value
$251.41+0.62 (+0.25%)
Close on Nov 18, 2026Market cap $37.16BP/E 107.4Yield –
Biogen revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Biogen's revenue for the twelve months ending Sep 30, 2026 was $10.30B, up 2.3% year over year. For fiscal 2025 it was $9.89B, up 2.2% from the year before. Over ten years it grew -0.8% a year on average. The highest annual figure on record is $14.38B in fiscal 2019.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.89B | +2.2% |
| FY2024 | Dec 31, 2024 | $9.68B | -1.6% |
| FY2023 | Dec 31, 2023 | $9.84B | -3.3% |
| FY2022 | Dec 31, 2022 | $10.17B | -7.4% |
| FY2021 | Dec 31, 2021 | $10.98B | -18.3% |
| FY2020 | Dec 31, 2020 | $13.44B | -6.5% |
| FY2019 | Dec 31, 2019 | $14.38B | +6.9% |
| FY2018 | Dec 31, 2018 | $13.45B | +9.6% |
| FY2017 | Dec 31, 2017 | $12.27B | +7.2% |
| FY2016 | Dec 31, 2016 | $11.45B | +6.4% |
| FY2015 | Dec 31, 2015 | $10.76B | +10.9% |
| FY2014 | Dec 31, 2014 | $9.70B | +40.0% |
| FY2013 | Dec 31, 2013 | $6.93B | +25.7% |
| FY2012 | Dec 31, 2012 | $5.52B | +9.3% |
| FY2011 | Dec 31, 2011 | $5.05B | +7.0% |
| FY2010 | Dec 31, 2010 | $4.72B | +7.7% |
| FY2009 | Dec 31, 2009 | $4.38B | +6.8% |
| FY2008 | Dec 31, 2008 | $4.10B | +29.2% |
| FY2007 | Dec 31, 2007 | $3.17B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.80B | +10.6% |
| Q2 FY2026 | Jun 30, 2026 | $2.74B | +3.4% |
| Q1 FY2026 | Mar 31, 2026 | $2.48B | +1.9% |
| Q4 FY2025 | Dec 31, 2025 | $2.28B | -7.1% |
| Q3 FY2025 | Sep 30, 2025 | $2.53B | +2.8% |
| Q2 FY2025 | Jun 30, 2025 | $2.65B | +7.3% |
| Q1 FY2025 | Mar 31, 2025 | $2.43B | +6.1% |
| Q4 FY2024 | Dec 31, 2024 | $2.45B | +2.9% |
| Q3 FY2024 | Sep 30, 2024 | $2.47B | -2.5% |
| Q2 FY2024 | Jun 30, 2024 | $2.46B | +0.4% |
| Q1 FY2024 | Mar 31, 2024 | $2.29B | -7.0% |
| Q4 FY2023 | Dec 31, 2023 | $2.39B | -6.2% |
| Q3 FY2023 | Sep 30, 2023 | $2.53B | +0.9% |
| Q2 FY2023 | Jun 30, 2023 | $2.46B | -5.1% |
| Q1 FY2023 | Mar 31, 2023 | $2.46B | -2.7% |
| Q4 FY2022 | Dec 31, 2022 | $2.54B | -6.9% |
| Q3 FY2022 | Sep 30, 2022 | $2.51B | -9.7% |
| Q2 FY2022 | Jun 30, 2022 | $2.59B | -6.7% |
| Q1 FY2022 | Mar 31, 2022 | $2.53B | -6.0% |
| Q4 FY2021 | Dec 31, 2021 | $2.73B | -4.2% |
| Q3 FY2021 | Sep 30, 2021 | $2.78B | -17.7% |
| Q2 FY2021 | Jun 30, 2021 | $2.78B | -24.6% |
| Q1 FY2021 | Mar 31, 2021 | $2.69B | -23.8% |
| Q4 FY2020 | Dec 31, 2020 | $2.85B | -22.3% |
| Q3 FY2020 | Sep 30, 2020 | $3.38B | -6.2% |
| Q2 FY2020 | Jun 30, 2020 | $3.68B | +1.8% |
| Q1 FY2020 | Mar 31, 2020 | $3.53B | +1.3% |
| Q4 FY2019 | Dec 31, 2019 | $3.67B | +4.1% |
| Q3 FY2019 | Sep 30, 2019 | $3.60B | +4.7% |
| Q2 FY2019 | Jun 30, 2019 | $3.62B | +7.8% |
| Q1 FY2019 | Mar 31, 2019 | $3.49B | +11.5% |
| Q4 FY2018 | Dec 31, 2018 | $3.53B | +6.6% |
| Q3 FY2018 | Sep 30, 2018 | $3.44B | +11.7% |
| Q2 FY2018 | Jun 30, 2018 | $3.36B | +9.0% |
| Q1 FY2018 | Mar 31, 2018 | $3.13B | +11.4% |
| Q4 FY2017 | Dec 31, 2017 | $3.31B | +15.1% |
| Q3 FY2017 | Sep 30, 2017 | $3.08B | – |
| Q2 FY2017 | Jun 30, 2017 | $3.08B | – |
| Q1 FY2017 | Mar 31, 2017 | $2.81B | – |
| Q4 FY2016 | Dec 31, 2016 | $2.87B | – |
See a number that looks wrong?